NextCure's SIM0505 Shows 55% ORR in Gynecologic Cancers in Positive Phase 1 Data at ASCO
NXTC sits 35% above its 52-week low of $4.6 on light trading volume (0.2× avg).
Summary
NextCure presented positive Phase 1 dose escalation data for its investigational antibody drug conjugate (ADC), SIM0505, at ASCO 2026. The drug achieved an Objective Response Rate (ORR) of 55% in gynecologic cancers, including 52.9% in ovarian cancer and 66.7% in uterine serous carcinoma, in heavily pre-treated patients. This follows the Fast Track Designation for SIM0505 announced in April and the company's recent Q1 report which reiterated a going concern warning. These strong early efficacy results in a high unmet need area are highly significant for the micro-cap biotech, potentially validating the drug's platform and improving prospects for future financing or partnerships. NextCure plans to host a virtual KOL Event on June 2, 2026, to review these data.
At the time of this announcement, NXTC was trading at $6.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.4M. The 52-week trading range was $4.60 to $15.74. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.